Aldevron News / Aldevron

Aldevron Promotes Venkata Indurthi to Vice President of Research and Development

Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, has promoted Venkata Indurthi to Vice President of Research and Development (R&D).  He will begin this new role immediately and continue reporting to John Ballantyne, Co-founder and Chief Scientific Officer while having direct access to Aldevron’s senior executive team. 

Read More

In the news: Pharma's Almanac - CRISPR RNPs and the Future of Cell and Gene Therapy

As clustered regularly interspaced short palindromic repeats (CRISPR) therapies progress to the clinic, the key CRISPR editing components are primarily being delivered by recombinant virus, RNA, or as ribonucleoprotein (RNP), which is the active complex formed by the guide RNA and Cas9 protein. RNPs have several attractive properties as a delivery format, particularly in the manufacturing of ex vivo cellular therapies, the most rapidly growing segment of the CRISPR therapeutics market.

Read More

Webinar Highlights Potential of Researcher-CMO Collaboration in Gene Editing Therapy

As a Project Scientist for the University of California, Los Angeles, Dr. Mark DeWitt has developed a phase 1 GMP-compatible protocol for correcting diseases that cause gene mutations using a CRISPR-Cas9 modular, non-viral gene editing platform. His specific research focuses on a treatment for sickle cell anemia that is more accessible and less costly than a bone marrow transplant—currently, the only way to address the disease. 

Over the past year, DeWitt has partnered with Aldevron and Synthego, industry leaders in CRISPR-Cas9 nucleases and gRNA manufacturing, respectively.

Read More

Aldevron to Divest its Antibody Discovery Unit

Aldevron, a leading manufacturer of plasmid DNA, proteins and mRNA, today announced the sale of its Germany based antibody discovery businessBrian Walters, current president of the business unit and longtime employee of Aldevronled a group of investors to purchase the business for an undisclosed amount. The transaction is effective immediately.  

Read More

Aldevron The First To Rapidly Discover Human Antibodies Using Ligands Omnirat® Platform And Berkeley Lights Beacon® Instrument

Aldevron, a leading provider of antibody discovery and production services, today announced the successful discovery of human antibodies utilizing the combination of three powerful platforms, Aldevron’s GENOVAC® genetic immunization and cell-based screening, Ligand’s OmniRat® therapeutic antibody platform and Berkeley Lights’ Beacon® platform.

Read More

Aldevron's Antibody Discovery Team Participating at PEGS

Patricia Odermatt, Senior B-cell Scientist with Aldevron’s Antibody business unit, will be presenting at the  PEGS Boston Summit at 11:30 EDT on Monday, August 31. Her presentation,  Rapid Human Antibody Discovery Utilizing Ligand’s OmniRat® Platform and Berkeley Lights’ Beacon® Instrument will show how three antibody discovery platforms are being used together in developing fully human antibodies against SARS-CoV-2 targets. Patricia will be available at the Aldevron digital booth for additional discussions throughout PEGS. The presentation is only available to those registered for PEGS, which you can find here. However, anyone can connect with our Antibody team at any time through our contact form.
Read More

In the news: Bloomberg Law - Aldevron Taps Legal Chief, Looks for Possible Covid Vaccine Role

Aldevron LLC, a company angling for a role in the production of Covid-19 vaccines, hired Rachel Lei as its first general counsel and corporate secretary.

Lei became Aldevron’s first general counsel in June. She joins new chief executive officer Kevin Ballinger, hired the following month, among other recent additions to the North Dakota-based company’s leadership team.

Read More